

Dirk Daelemans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1001298/publications.pdf>

Version: 2024-02-01

141
papers

7,618
citations

109264

35
h-index

58549

82
g-index

154
all docs

154
docs citations

154
times ranked

13581
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of (±)-3-(1H-pyrazol-1-yl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine derivatives with promising in vitro anticoronavirus and antitumoral activity. <i>Molecular Diversity</i> , 2022, 26, 1357-1371.	2.1	11
2	Target Identification of Small Molecules Using Large-Scale CRISPR-Cas Mutagenesis Scanning of Essential Genes. <i>Methods in Molecular Biology</i> , 2022, 2377, 43-67.	0.4	1
3	Anthranilamides with quinoline and β^2 -carboline scaffolds: design, synthesis, and biological activity. <i>Molecular Diversity</i> , 2022, 26, 2595-2612.	2.1	3
4	The T850D Phosphomimetic Mutation in the Androgen Receptor Ligand Binding Domain Enhances Recruitment at Activation Function 2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1557.	1.8	3
5	Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules. <i>Biomedicines</i> , 2022, 10, 1057.	1.4	5
6	Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential anti-HIV agents with reduced cytotoxicity. <i>Chemical Biology and Drug Design</i> , 2021, 97, 67-76.	1.5	16
7	Synthesis, in silico ADME, molecular docking and in vitro cytotoxicity evaluation of stilbene linked 1,2,3-triazoles. <i>Heliyon</i> , 2021, 7, e05893.	1.4	3
8	Loss of tRNA-modifying enzyme Etp3 activates a p53-dependent antitumor checkpoint in hematopoiesis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	14
9	Intermedilysin cytolytic activity depends on heparan sulfates and membrane composition. <i>PLoS Genetics</i> , 2021, 17, e1009387.	1.5	6
10	XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. <i>Blood Cancer Journal</i> , 2021, 11, 27.	2.8	3
11	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. <i>Nature Genetics</i> , 2021, 53, 435-444.	9.4	162
12	New cytotoxic ent-kauranes with unprecedented pharmacophores. , 2021, , .		0
13	Preparation of Antiproliferative Terpene-Alkaloid Hybrids by Free Radical-Mediated Modification of ent-Kauranic Derivatives. <i>Molecules</i> , 2021, 26, 4549.	1.7	2
14	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13604-13621.	2.9	10
15	Cellular host factors for SARS-CoV-2 infection. <i>Nature Microbiology</i> , 2021, 6, 1219-1232.	5.9	127
16	Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113540.	2.6	15
17	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113727.	2.6	9
18	enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9. <i>Molecular Therapy</i> , 2021, 29, 208-224.	3.7	8

#	ARTICLE	IF	CITATIONS
19	Synthesis, Computational Analysis, and Antiproliferative Activity of Novel Benzimidazole Acrylonitriles as Tubulin Polymerization Inhibitors: Part 2. <i>Pharmaceuticals</i> , 2021, 14, 1052.	1.7	6
20	Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones. <i>Pharmaceuticals</i> , 2021, 14, 1131.	1.7	5
21	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1338-1348.	3.2	28
22	Iron/Copper Co-Catalyzed Cross-Coupling Reaction for the Synthesis of 6-Substituted 7-Deazapurines and the Corresponding Nucleosides. <i>Journal of Organic Chemistry</i> , 2020, 85, 403-418.	1.7	14
23	Drug repurposing: phosphate prodrugs of anticancer and antiviral FDA-approved nucleosides as novel antimicrobials. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2864-2878.	1.3	10
24	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1605-1610.	1.3	5
25	Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112638.	2.6	14
26	Synthesis of Novel Nitroxoline Analogs with Potent Cathepsin B Exopeptidase Inhibitory Activity. <i>ChemMedChem</i> , 2020, 15, 2477-2490.	1.6	6
27	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127287.	1.0	3
28	Bicyclic β -lminophosphonates as High Affinity Imidazoline K_{2} Receptor Ligands for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3610-3633.	2.9	17
29	<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. <i>Brain Communications</i> , 2020, 2, fcaa064.	1.5	33
30	Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration. <i>Bio-protocol</i> , 2020, 10, e3659.	0.2	2
31	C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport. <i>Scientific Reports</i> , 2019, 9, 15728.	1.6	47
32	STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes. <i>EMBO Reports</i> , 2019, 20, e48150.	2.0	34
33	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2083-2098.	2.9	66
34	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1450-1453.	1.0	6
35	Synthesis and cytotoxic evaluation of monocarbonyl curcuminoids and their pyrazoline derivatives. <i>Monatshefte für Chemie</i> , 2019, 150, 2045-2051.	0.9	8
36	Design and Synthesis of New 6-Nitro and 6-Amino-3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole Derivatives: Antiproliferative and Antibacterial Activity. <i>Molecules</i> , 2019, 24, 4236.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 447-456.	1.4	24
38	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. <i>Chemical Biology and Drug Design</i> , 2019, 93, 430-437.	1.5	13
39	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1348-1351.	1.0	13
40	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the NNRTI Adjacent Binding Site. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 334-338.	1.3	32
41	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 370-375.	1.3	28
42	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2051-2060.	1.4	10
43	Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. <i>Nature Communications</i> , 2018, 9, 502.	5.8	84
44	Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored hydrophobic channel. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 1014-1028.	1.5	26
45	Near-native, site-specific and purification-free protein labeling for quantitative protein interaction analysis by MicroScale Thermophoresis. <i>Scientific Reports</i> , 2018, 8, 4977.	1.6	60
46	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 339-350.	2.6	68
47	To disinfect or not to disinfect in postharvest research on the fungal decay of apple?. <i>International Journal of Food Microbiology</i> , 2018, 266, 190-199.	2.1	11
48	Synthesis and Biological Evaluation of Pyrrolo[2,1- <i>b</i>][1,2,4]triazine- <i>C</i> -Nucleosides with a Ribose, 2-Deoxyribose, and 2,3-Dideoxyribose Sugar Moiety. <i>ChemMedChem</i> , 2018, 13, 97-104.	1.6	17
49	Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	30
50	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2- <i>d</i>]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. <i>Chemical Biology and Drug Design</i> , 2018, 92, 2009-2021.	1.5	16
51	5-Hydroxypyrido[2,3- <i>b</i>]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 714-724.	2.6	31
52	Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. <i>Oncotarget</i> , 2018, 9, 35327-35342.	0.8	11
53	Structure-Based Optimization of Thiophene[3,2- <i>d</i>]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4424-4443.	2.9	79
54	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4397-4406.	1.4	23

#	ARTICLE	IF	CITATIONS
55	Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. <i>Molecular Cell</i> , 2017, 65, 1044-1055.e5.	4.5	437
56	The stem cell growth factor receptor <scp>KIT</scp> is not expressed on interstitial cells in bladder. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1206-1216.	1.6	17
57	Discovery of Thiophene[3,2- <i>d</i>]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1188-1193.	1.3	30
58	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 383-391.	2.6	12
59	The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2528-2541.	3.2	52
60	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 190-201.	2.6	17
61	Comparative study of the organisation and phenotypes of bladder interstitial cells in human, mouse and rat. <i>Cell and Tissue Research</i> , 2017, 370, 403-416.	1.5	8
62	Abstract 5224: Identification of drug-target interactions through rapid selection of drug resistant protein variants generated by CRISPR/Cas9-induced NHEJ. , 2017, , .		0
63	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. <i>Chemical Biology and Drug Design</i> , 2016, 87, 283-289.	1.5	8
64	Design, synthesis, and biological evaluation of novel 5-alkyl-6-adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors. <i>Chemical Biology and Drug Design</i> , 2016, 88, 380-385.	1.5	2
65	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 352-363.	2.6	27
66	l-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2142-2146.	1.0	12
67	XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. <i>Nature</i> , 2016, 538, 114-117.	13.7	162
68	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4424-4433.	1.4	12
69	Design, Synthesis, and Evaluation of Thiophene[3,2- <i>d</i>]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7991-8007.	2.9	107
70	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5- <i>b</i>]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. <i>Chemical Biology and Drug Design</i> , 2016, 88, 241-253.	1.5	12
71	The Oxygen Sensor PHD2 Controls Dendritic Spines and Synapses via Modification of Filamin A. <i>Cell Reports</i> , 2016, 14, 2653-2667.	2.9	46
72	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 53-62.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 294-304.	2.6	28
74	Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export. <i>Oncotarget</i> , 2016, 7, 68842-68850.	0.8	20
75	Abstract LB-210: KPT-8602 is a second-generation XPO1 inhibitor with improved in vivo tolerability that demonstrates potent acute lymphoblastic leukemia activity. , 2016, , .		0
76	Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells. <i>Biochemical Pharmacology</i> , 2015, 96, 190-201.	2.0	2
77	Scaffold hopping: Exploration of acetanilide-containing uracil analogues as potential NNRTIs. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1069-1081.	1.4	14
78	Synthesis and biological evaluation of DAPYâ€“DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 624-631.	1.4	13
79	Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. <i>Chemistry and Biology</i> , 2015, 22, 107-116.	6.2	108
80	Hybrid chemistry. Part 4: Discovery of etravirineâ€“VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4248-4255.	1.4	25
81	Anti-HIV diarylpyrimidineâ€“quinolone hybrids and their mode of action. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3860-3868.	1.4	25
82	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 1-9.	2.6	23
83	Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma. <i>EBioMedicine</i> , 2015, 2, 1102-1113.	2.7	24
84	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue. <i>European Journal of Medicinal Chemistry</i> , 2015, 102, 215-222.	2.6	23
85	Abstract 2442: XPO1 is selinexor prime target: validation by mutating cysteine 528 on both XPO1 alleles using CRISPR/Cas9 genome editing. , 2015, , .		0
86	Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma. <i>Blood</i> , 2015, 126, 2751-2751.	0.6	1
87	Dynamics of the Ternary Complex Formed by c-Myc Interactor JPO2, Transcriptional Co-activator LEDGF/p75, and Chromatin. <i>Journal of Biological Chemistry</i> , 2014, 289, 12494-12506.	1.6	11
88	A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. <i>Antiviral Research</i> , 2014, 112, 91-102.	1.9	24
89	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. <i>MedChemComm</i> , 2014, 5, 468.	3.5	6
90	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4658-4666.	1.4	19

#	ARTICLE	IF	CITATIONS
91	Anti-HIV-1 activity of the G-quadruplex ligand BRACO-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3248-3258.	1.3	115
92	Identification of Different Phenotypes of Interstitial Cells in the Upper and Deep Lamina Propria of the Human Bladder Dome. <i>Journal of Urology</i> , 2014, 192, 1555-1563.	0.2	45
93	HIV-1 Rev Multimerization: Mechanism and Insights. <i>Current HIV Research</i> , 2014, 11, 623-634.	0.2	18
94	Role of PFKFB3-Driven Glycolysis in Vessel Sprouting. <i>Cell</i> , 2013, 154, 651-663.	13.5	1,117
95	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: Synthesis, biological investigation and molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6477-6483.	1.4	8
96	Optical coherence tomography visualizes microstructure of apple peel. <i>Postharvest Biology and Technology</i> , 2013, 78, 123-132.	2.9	66
97	Hemozoin Induces Lung Inflammation and Correlates with Malaria-Associated Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 48, 589-600.	1.4	76
98	Some Hydrazones of 2- <i>N</i> -Aroylamino- <i>N</i> -methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV-1. <i>Archiv Der Pharmazie</i> , 2013, 346, 140-153.	2.1	5
99	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 65, 134-143.	2.6	19
100	Mapping the Binding Interface between an HIV-1 Inhibiting Intrabody and the Viral Protein Rev. <i>PLoS ONE</i> , 2013, 8, e60259.	1.1	12
101	Intracytoplasmic Trapping of Influenza Virus by a Lipophilic Derivative of Aglycoristocetin. <i>Journal of Virology</i> , 2012, 86, 9416-9431.	1.5	31
102	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 485-492.	2.6	5
103	CXCR4 chemokine receptor antagonists: nickel(ii) complexes of configurationally restricted macrocycles. <i>Dalton Transactions</i> , 2012, 41, 11369.	1.6	35
104	Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 4621-4634.	0.6	253
105	A phenyl-thiadiazolylidene-amine derivative ejects zinc from retroviral nucleocapsid zinc fingers and inactivates HIV virions. <i>Retrovirology</i> , 2012, 9, 95.	0.9	24
106	Computational investigation of the HIV-1 Rev multimerization using molecular dynamics simulations and binding free energy calculations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2012, 80, 1633-1646.	1.5	9
107	A time-of- <i>drug</i> addition approach to target identification of antiviral compounds. <i>Nature Protocols</i> , 2011, 6, 925-933.	5.5	108
108	Selective inhibition of Human Immunodeficiency Virus type 1 (HIV-1) by a novel family of tricyclic nucleosides. <i>Antiviral Research</i> , 2011, 92, 37-44.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6-Naphthyridone Derivative with Potent and Selective Anti-HIV Activity. <i>ChemMedChem</i> , 2011, 6, 1249-1257.	1.6	30
110	Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. <i>RNA Biology</i> , 2011, 8, 316-324.	1.5	10
111	Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. <i>Antiviral Research</i> , 2010, 85, 418-421.	1.9	20
112	Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives. <i>ChemMedChem</i> , 2010, 5, 1880-1892.	1.6	26
113	Inside Cover: Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives (ChemMedChem 11/2010). <i>ChemMedChem</i> , 2010, 5, 1798-1798.	1.6	0
114	An Intrabody Based on a Llama Single-domain Antibody Targeting the N-terminal α -Helical Multimerization Domain of HIV-1 Rev Prevents Viral Production. <i>Journal of Biological Chemistry</i> , 2010, 285, 21768-21780.	1.6	60
115	Inhibition of HIV-1 Replication by a Bis-Thiadiazolbenzene-1,2-Diamine That Chelates Zinc Ions from Retroviral Nucleocapsid Zinc Fingers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1461-1468.	1.4	34
116	A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 641-648.	2.9	122
117	Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanions. <i>Antiviral Research</i> , 2009, 83, 61-70.	1.9	10
118	Studies on anti-HIV quinolones: New insights on the C-6 position. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 667-674.	1.4	32
119	Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure-activity relationship and mechanism of action. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9487-9497.	1.4	59
120	Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. <i>Nature Protocols</i> , 2008, 3, 427-434.	5.5	324
121	Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. <i>Journal of Virological Methods</i> , 2008, 151, 66-73.	1.0	21
122	Structure-Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5454-5458.	2.9	56
123	Specific Targeting of the F13L Protein by St-246 Affects Orthopoxvirus Production Differently. <i>Antiviral Therapy</i> , 2008, 13, 977-990.	0.6	22
124	The Nucleotide Analog Cidofovir Suppresses Basic Fibroblast Growth Factor (FGF2) Expression and Signaling and Induces Apoptosis in FGF2-Overexpressing Endothelial Cells. <i>Molecular Pharmacology</i> , 2007, 71, 695-703.	1.0	10
125	Characterization of a Replication-Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors. <i>Journal of Virology</i> , 2007, 81, 4381-4385.	1.5	21
126	Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2007, 81, 362-373.	1.5	99

#	ARTICLE	IF	CITATIONS
127	Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. <i>Virology</i> , 2007, 366, 40-50.	1.1	70
128	Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. <i>Journal of Clinical Investigation</i> , 2007, 117, 3453-3462.	3.9	283
129	Mouse adenovirus type 1 attachment is not mediated by the coxsackie-adenovirus receptor. <i>FEBS Letters</i> , 2006, 580, 3937-3942.	1.3	14
130	HIV-1 Rev function as target for antiretroviral drug development. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 388-397.	1.5	3
131	A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors. <i>Molecular Pharmacology</i> , 2005, 67, 1574-1580.	1.0	18
132	Kinetic and Molecular Analysis of Nuclear Export Factor CRM1 Association with Its Cargo In Vivo. <i>Molecular and Cellular Biology</i> , 2005, 25, 728-739.	1.1	58
133	In Vivo HIV-1 Rev Multimerization in the Nucleolus and Cytoplasm Identified by Fluorescence Resonance Energy Transfer. <i>Journal of Biological Chemistry</i> , 2004, 279, 50167-50175.	1.6	53
134	Automatic and Quantitative Measurement of Protein-Protein Colocalization in Live Cells. <i>Biophysical Journal</i> , 2004, 86, 3993-4003.	0.2	1,235
135	A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14440-14445.	3.3	120
136	2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. <i>Antiviral Research</i> , 2002, 55, 413-424.	1.9	46
137	A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. <i>Journal of Virological Methods</i> , 2001, 96, 183-188.	1.0	26
138	Human Immunodeficiency Virus Gene Regulation as a Target for Antiviral Chemotherapy. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 1-14.	0.3	33
139	Stereospecificity of 6'-C-Neplanocin A Analogues as Inhibitors of S-Adenosylhomocysteine Hydrolase Activity and Human Immunodeficiency Virus Replication. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 1998, 17, 479-486.	0.4	3
140	Cell Type-Dependent Effect of Sodium Valproate on Human Immunodeficiency Virus Type 1 Replication <i>in Vitro</i> . <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 187-192.	0.5	47
141	Adenosylhomocysteine Hydrolase Inhibitors Interfere with the Replication of Human Immunodeficiency Virus Type 1 through Inhibition of the LTR Transactivation. <i>Molecular Pharmacology</i> , 1997, 52, 1157-1163.	1.0	27